Published December 31, 2020 | Version v1
Project deliverable Open

CAPABLE D8.2: Market Analysis V2

  • 1. Universidad Politécnica de Madrid, Spain
  • 2. University of Pavia, Italy
  • 3. University of Haifa, Israel
  • 4. Academic Medical Center Amsterdam (AMC), The Netherlands
  • 5. IBM Research - Haifa, Israel
  • 6. Bitsens, Lithuania
  • 7. Poznan University of Technology, Poland
  • 8. Istituti Clinici Scientifici Maugeri (ICS Maugeri), Italy
  • 9. Netherlands Cancer Institute (NKI), The Netherlands
  • 10. Denotics, UK
  • 11. Aimac, Italy


The document shows the activities of market research performed in the second half of the first year of the project. Differently from the initial deliverable (D8.1): the focus of the market research has been to study the specific costs of kidney and melanoma cancer, and the possible barriers and success criteria to market to then continue the CAPABLE roadmap to the adoption following the CEHRES method presented in D8.1. The document also presents an update of the technology vigilance, which also contains a specific selection of solutions that are relevant competitors of CAPABLE and a study of the existing solution in the 2 hospitals of CAPABLE (ICSM and NKI-NVL). The document also presents an updated version of the Consortium IPR strategy and questionnaire interviews to be launched next year to start exploiting interests from key decision makers.


This deliverable is a part of a project receiving funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 875052



Files (1.4 MB)

Name Size Download all
1.4 MB Preview Download

Additional details


CAPABLE – CAncer PAtients Better Life Experience 875052
European Commission